Eltanexor Plus Inqovi

A Phase I/II Trial of Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
80 patients (estimated)
Sponsors
National Cancer Institute (NCI)
Tags
Chemotherapy, Cytidine Deaminase Inhibitor (CDAi), Nucleoside Metabolic Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1733
NCT Identifier
NCT05918055

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.